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Abstract: Pandemic SARS-CoV-2 causes a mild to severe respiratory disease called coronavirus dis-
ease 2019 (COVID-19). While control of the SARS-CoV-2 spread partly depends on vaccine-induced 
or naturally acquired protective herd immunity, antiviral strategies are still needed to manage 
COVID-19. Enisamium is an inhibitor of influenza A and B viruses in cell culture and clinically 
approved in countries of the Commonwealth of Independent States. In vitro, enisamium acts 
through metabolite VR17-04 and inhibits the activity of the influenza A virus RNA polymerase. 
Here we show that enisamium can inhibit coronavirus infections in NHBE and Caco-2 cells, and the 
activity of the SARS-CoV-2 RNA polymerase in vitro. Docking and molecular dynamics simulations 
provide insight into the mechanism of action and indicate that enisamium metabolite VR17-04 pre-
vents GTP and UTP incorporation. Overall, these results suggest that enisamium is an inhibitor of 
SARS-CoV-2 RNA synthesis in vitro. 




Severe acute respiratory coronavirus 2 (SARS-CoV-2) is an important human patho-
gen and the causative agent of coronavirus disease 2019 (COVID-19). Vaccines are avail-
able to prevent the spread of SARS-CoV-2, and several antiviral strategies, such as treat-
ment with remdesivir or reconvalescent plasma, have received FDA approval or emer-
gency use approval. However, the development of additional strategies remains neces-
sary, because of the continuous emergence of variants of concern (VOC) and current an-
tiviral treatments can only be delivered intravenously. A key target for novel drug screen-
ing is the RNA polymerase of SARS-CoV-2 [1–4]. 
SARS-CoV-2 is a betacoronavirus and contains a positive-sense, non-segmented 
RNA genome of around 30 kilobases [5,6]. The 5′ two-thirds of the viral genome encodes 
two overlapping open reading frames (ORFs), 1a and 1b, which are translated into two 
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large polyproteins by host cell ribosomes. The two polyproteins are cleaved by intrinsic 
proteolytic activity to produce 16 non-structural proteins (nsps). Nsp12 is the RNA-de-
pendent RNA polymerase that copies and transcribes the SARS-CoV-2 genome [7,8]. 
Nsp12 requires nsp7 and nsp8 for processivity in vitro [9]. The structures of nsp12/7/8 
from SARS-CoV and SARS-CoV-2 were solved by cryo-EM [10–12]. 
Various nucleoside analogues and small molecule inhibitors were identified as po-
tential inhibitors of the SARS-CoV-2 nsp12/7/8 complex [1–3]. One of the drugs high-
lighted by the World Health Organization as a candidate therapeutic against SARS-CoV-
2 is enisamium (4-(benzylcarbamoyl)-1-methylpyridinium); Figure 1A). Enisamium is li-
censed for use against influenza in 11 countries and it was shown to reduce virus shedding 
and improve influenza patient recovery [13]. A recent study found that enisamium is hy-
droxylated in humans and human lung cells to a compound called VR17-04 (Figure 1A) 
[13]. VR17-04 inhibits the activity of the influenza virus RNA polymerase [13]. 
 
Figure 1. Enisamium inhibits SARS-CoV-2 infection of Caco-2 cells in vitro. (A) Chemical structures 
of enisamium iodide (FAV00A) and VR17-04. The chemical structure of FAV00B is identical to 
FAV00A except that chloride ions are present instead of iodide. (B) Inhibition of SARS-CoV-2 N 
expression by enisamium chloride in Caco-2 cells. (C) Inhibition of SARS-CoV-2 cytopathic effect 
by enisamium iodide and chloride in Caco-2 cells. (D) Effect of enisamium iodide or (E) enisamium 
chloride on SARS-CoV-2 infected Caco-2 cells. 
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In this study, we show that enisamium inhibits coronavirus growth on Caco-2 and 
normal human bronchial epithelial (NHBE) cells. We also demonstrate that enisamium 
inhibits the minimal viral RNA polymerase complex in a mini-genome assay. Molecular 
dynamics (MD) simulation analysis suggests that VR17-04 reversibly binds to the exposed 
cytosine or adenine bases, preventing incorporation of GTP and UTP into the nascent 
strand. Overall, these results suggest that enisamium prevents SARS-CoV-2 RNA synthe-
sis by inhibiting nascent strand elongation. 
2. Materials and Methods 
2.1. SARS-CoV-2 Infections 
Confluent layers of Caco-2 cells in 96-well plates were treated with serial dilutions of 
enisamium iodide (laboratory code FAV00A, trade name Amizon®) or enisamium chlo-
ride (laboratory code FAV00B) 6 h prior to infection. The cells were infected with SARS-
CoV-2 at multiplicity of infection 0.01 for 1 h, and compound reapplied following virus 
removal. At 48 h post infection, the cytopathic effect was recorded by examination of the 
infected cultures by light microscopy and supernatant collected to quantify virus RNA by 
RT-qPCR as described previously, using nsp12-specific primers 5′-
GTGARATGGTCATGTGTGGCGG-3′ and 5′-CARATGTTAAASACACTATTAGCATA-
3′ [13–21]. Cells were fixed with acetone/methanol (40:60) and immunostained using a 
SARS-CoV-2 nucleoprotein monoclonal antibody (1:500, Sinobiological, Cat #40143-R019-
100 µL). Staining was detected using a peroxidase conjugated anti-rabbit secondary anti-
body (1:1000, Dianova) and the addition of AEC substrate. 
2.2. HCoV-NL63 NHBE Infections 
MatTek’s EpiAirway System (MatTek; Ashland, MA, USA) consisted of differenti-
ated NHBE cells that were cultured to form a multilayered, highly differentiated model 
that closely resembles the epithelial tissue of the respiratory tract. The cells from a single 
donor (No. 9831) were used for assay consistency. The apical surface of the cells was ex-
posed to a humidified 95% air, 5% CO2 environment. The basolateral medium was 
changed, and the mucin layer was washed every 24–48 h. NHBE cells were inoculated via 
the exposure of the apical side to HCoV-NL63. After 1 h of incubation with virus in a 
water-jacketed 37 °C incubator with a 5% CO2 supply, the viral inoculum was removed 
from the cells. The apical side of the cells was washed once prior to infection. After viral 
inoculation, enisamium chloride or control media were added to the apical side of the cells 
and the basal media compartment and incubated with the cells for 1 h. After a 1-hour 
incubation, the drug containing media was removed from apical and basal chambers. 
Growth medium alone or growth medium with enisamium chloride were added to the 
bottom chamber, and cells were incubated for 48 h. At the termination of the experiments, 
cells were washed twice, then 1 mL Trizol (Thermo Fisher; Waltham, MA, USA) was 
added to each well for RNA isolation. Total RNA was isolated from cells using Trizol per 
the manufacturer’s instruction. Two-step RT-qPCR was performed using HCoV-NL63 N 
gene-specific primers/probe (forward primer: 5′-TGGTGTTGTTTGGGTTGCTA-3′, re-
verse primer 5′-GCTCTGGAGGCAAAGCAATA-3′, double-quenched probe: 5′-
FAM/CGCAAACGT/ZEN/AATCAGAAACCTTTGGA/IABKFQ-3′), GAPDH was ana-
lyzed at the same time with GAPDH-specific primers (5′-GTTCGACAGTCAGCCG-
CATC-3′ and 5′-AGTTAAAAGCAGCCCTGGTGA-3′) by RT-qPCR and served as a refer-
ence gene for normalization. 
2.3. SARS-CoV-2 Minigenome Assay 
The SARS-CoV-2 mini-genome assay was performed as described previously [14]. 
Briefly, approximately 2 × 105 HEK 293T cells were transfected with 200 ng pcDNA6.B-
nsp7-flag, pcDNA6.B-nsp8-flag, and pcDNA6.B-nsp12-flag, and 25 ng linear pPolI-SARS-
CoV2-NLuc-N plasmid using Lipofectamine 2000 (Thermo Fisher). Cells were collected 
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24 h post-transfection and analyzed using a Nano-Glo dual-luciferase reporter assay (Cat-
alogue number N1610; Promega; Madison, WI, USA) according to the manufacturer’s pro-
tocol and a Glomax navigator microplate Luminometer (Promega). For each condition, 
three biological replicates were conducted. 
2.4. NOE NMR Spectra Measurement 
The VR17-04 (2 mg) was dissolved in 0.6 mL D2O/water solution (5% D2O) or DMSO. 
NMR experiments were performed at 500 MHz at 277 K. For NOESY experiments (noe-
sygpph) 128 transients were collected for each free-induction decay, using a mixing time 
of 300 ms and 20 sec of relaxation delay. The NOESY experiment (matrix 1024 × 320 points) 
was zero-filled to 2K × 2K before Fourier transformation. Measurements were taken on a 
Bruker 500 HD NMR spectrometer equipped with a 5 mm BB probe. 
2.5. Conformational Characterization and Geometry Optimization 
The VR17-04 and enisamium conformational characterization and geometry optimi-
zation was performed using the quantum chemical approach DFT B3LYP/6-31G*. The 
quantum chemistry software GAUSSIAN 2016 was used at this stage [22]. The explored 
conformations of VR17-04 and enisamium are characterized by the dihedral angles de-
fined by the following consecutive four atoms indicated in bold: φ0 (C(Ar)H-C(Ar)-
C(CH2)-N) φ1 (C(Ar)-C(CH2)-N-H), φ2 (H-N-C-O), φ3 (O-C-C(Ar)-C(Ar)OH/H). The low-
est energy conformation of VR17-04 (φ3 eclipsed) and enisamium were selected for further 
docking and for partial charge estimation (Table 1). 
Table 1. Quantum chemical (DFT B3LYP/6-31G*) geometry optimization of VR17-04 and enisamium. The dihedral angles 
(φ0, φ1, φ2, φ3) that define the conformation of VR17-04 and enisamium are reported. VR17-04 allows two conformations 
at φ3 trans and eclipsed, respectively. The estimated energies (EB3LYP) and zero-point energies (EZPE) are reported in Hartree. 
The ground state energy (EB3LYP + EZPE) are reported in Hartree. The energy difference between the two conformations 
(trans, eclipsed) in VR17-04 correspond to 0.0129 Hartree or 8.095 kcal mol−1). 
Compound φ0 φ1 φ2 φ3 Conf. EB3LYP (Hartree) EZPE (Hartree) EB3LYP+ EZPE (Hartree)  
VR17-04 80 44 148 141 trans −802.2589 0.2720 −801.9869 
VR17-04 83 9 177 −3 eclipsed −802.2713 0.2715 −801.9998 
Enisamium 77 27 170 −21 − −727.0392 0.2672 −726.7720 
2.6. Molecular Docking 
The docking simulation was performed using Autodock 4.2 software [23]. The geom-
etry of the ligands was previously optimized by DFT B3LYP/6-31G*. The geometry of the 
receptor RdRp was extracted from the PDB 7bv2 [24]. The catalytic site of the nsp12/7/8 
complex include the template RNA strand, the nascent strand RNA, the pyrophosphate 
moiety [O3P-O-PO3]−4 (pyr) and two Mg+2 ions, whose positions were included in 7BV2. 
The two Zn+2 ions that were co-crystallized in 7BV2 were also included in the models. The 
co-crystallized inhibitor remdesivir monophosphate was removed from the complex, 
while its position and the contacts with the template RNA through the unpaired uracil 
base in the +1 position were used to guide the molecular docking. The unpaired uracil 
base was subsequently mutated in cytosine (Cyt) or adenine (Ade) in Pymol 2.3.4 
(Schrodinger Inc; New York, NY, USA), generating two different complexes, identified as 
nsp12/7/8(Cyt) and nsp12/7/8(Ade), respectively. Next, Gasteiger charges were calculated 
for both ligands (VR17-04, enisamium) and the receptor complexes, and used as parame-
ters of the docking simulation [25]. In the docking simulation VR17-04 and enisamium 
were described by five and four rotational degrees of freedom, respectively. The docking 
gridbox was built by orthogonal hedges of length between 60 and 80 points. The gridbox 
centre was set to the NH2- group of the target cytosine or adenine residues of the template 
RNA strand, respectively, and further set-up to fit the space between the R555 and K545, 
Biomedicines 2021, 9, 1254 5 of 13 
 
and the uracil of the nascent RNA strand. The docking runs used the default genetic algo-
rithm search, with parameters: number of GA runs, population size, max number of en-
ergy evaluation, and max number of generations set as 100, 2000, 2.5 × 107, 270,000. At 
each run the docking solutions were clustered using a tolerance RMSD = 2.0 Å. Three dif-
ferent docking simulations were run: VR17-04 and enisamium were docked on to 
nsp12/7/8(Cyt), while, for comparison, VR17-04 was further docked on nsp12/7/8(Ade). 
The docking solutions were selected based on two criteria. The first criterium was the 
possibility to form a Watson–Crick base-pair interaction between VR17-04 (or enisamium) 
and the unpaired cytosine or adenine. The second criterium was based on the possibility 
to figure out interferences of the ligand with the catalytic mechanism, for example by in-
teraction with key residues of the nsp12/7/8 complex. The selected poses were further 
ranked by a preliminary MD simulation (approximately 50 ns) in explicit solvent, to pre-
dict the stability of the interaction, and to estimate the Poisson–Boltzmann free energy of 
binding, this last property was used to obtain a final selection and ranking of the poses. 
2.7. Molecular Dynamic Simulation 
Explicit solvent MD simulations were run using NAMD 2.12 [26] software and the 
Amber force-field (ff14SB) [27]. The TIP3P [28] water solvent model was used. The t-leap 
application of the Ambertools 14.0 package [27] was applied to generate the topology, the 
parameters, and the coordinate files of the macromolecular complex simulated. The coor-
dinates of the macromolecular elements of the nsp12/7/8 complex: nsp12, nsp8, nsp7, pyr, 
template RNA, and nascent strand RNA, were extracted from PDB 7bv2. The geometries 
of VR17-04, enisamium (before docking), and pyr were optimized using the quantum 
chemical approach DFT B3LYP/6-31G*; the corresponding partial charges were estimated 
by fitting the electrostatic potential that was calculated to the B3LYP/6-31G*/RHF/6-31G* 
model. This procedure is in accordance with the standard required by the Amber force-
field. The quantum chemistry software GAUSSIAN 2016 was used at this stage [22]. The 
Amber atomtypes (parm10.dat) were selected for VR17-04, enisamium, and pyr (ante-
chamber application, Ambertools 14.0). Three macromolecular complexes indicated as 
VR1704-nsp12/7/8(Cyt), enisamium-nsp12/7/8(Cyt), and VR1704-nsp12/7/8(Ade), were 
solvated by a 15 Å wide layer of TIP3P water molecules in each X, Y, Z direction; the 
orthogonal simulation box was built with hedges of approximate length 116, 116, 127 Å. 
The non-bond electrostatic and dispersive interactions were described by the standard 
cut-off technique (12.0 Å). Before running MD simulations, each simulation cell box was 
energy minimized by running 200 K steps of the default energy minimization algorithm, 
as implemented in NAMD. The MD simulations were run by fixing the number of parti-
cles (N), the absolute temperature (T), and the pressure (P) applied to the cell hedges. The 
absolute temperature was 300 K and maintained with a Lowe–Andersen thermostat, 
while the pressure on the cell box hedges was set as P = 1.01325 bar and preserved by the 
Nosé–Hoover–Langevin piston algorithm. The first MD simulation stage was run to ad-
just the simulation cell box density, allowing the relaxation of all the inter-molecule dis-
tances, i.e., the solute–solute, solute–solvent, and solvent–solvent distances. The cell den-
sity equilibration stage was run to restrain the atoms of the solute to their initial position 
(energy minimized geometry of the complex) by applying a harmonic restraint. In this 
stage of cell density equilibration, the water molecules were left free to move. The har-
monic restraint constant value was set initially at 1 Kcal mol−1 for each atom of the solute, 
and progressively reduced at 0.5 and 0.2 Kcal mol−1. The cell density equilibration stage 
was monitored by plotting the cell volume (Å3) vs. time (ns), until the cell volume fluctu-
ations level off to a horizontal axis that corresponds to the average final volume of the cell. 
This stage required between 20 and 50 ns approximately and was further checked by the 
formation of a thin water shell that surrounded the face of the inhibitor molecule that was 
exposed to the empty catalytic cavity of the nsp12/7/8 complex. In the second stage of the 
MD simulation, the harmonic restraint was removed, and the inhibitor-nsp12/7/8 complex 
was allowed to equilibrate in the geometry and the relative position of their elements: 
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inhibitor, template RNA, nascent strand RNA, pyr, Mg+2, and Zn+2. To monitor the equili-
bration of the position and orientation that VR17-04 (or enisamium) occupies in the +1 
position of the catalytic cavity, the distances between the carbonyl oxygen of VR17-04 and 
the hydrogen (NH2-) of cytosine (or adenine), and between the hydroxyl group of VR17-
04 and the nearby lone pair of cytosine nitrogen (or adenine), were plotted vs. simulation 
time. These distances provide a direct indication of the stability of the Watson–Crick base 
pair interaction that hold the inhibitor near the target base. The orientation of VR17-04 in 
the catalytic site of the nsp12 was also monitored by the coplanarity angle χ as defined by 
the following atoms in bold: CO-NH2-N-OH, in which CO and OH belong to VR17-04, 
while the remaining NH2 and N belong to the opposite cytosine (or adenine). Alterna-
tively, the enisamium-cytosine pair requires the following atoms CO-NH2-N-CH to define 
χ; in this case CO and CH belong to enisamium, while NH2 and N belong to the opposite 
cytosine. In fact, values of this angle around ‘0’ indicate that the ‘base pair’ contact be-
tween VR1704 the cytosine (or adenine) is coplanar, a geometric condition favoring the 
Watson–Crick ‘base-pair’ interaction between VR17-04 and the base. VMD 1.9.3 [29] was 
used for the MD simulation trajectory visualization and image creation. 
2.8. Estimation of Poisson-Boltzmann Free Energy of Binding 
In a system that evolves in accord to the complex formation reaction [30]. 
𝐿𝐿 + 𝑅𝑅 ⇆ 𝐿𝐿 − 𝑅𝑅 (1) 
The free energy change is calculated knowing only the initial and final state of the 
system: 
∆𝐺𝐺𝐵𝐵𝐵𝐵𝐵𝐵𝐵𝐵 = 𝐺𝐺(𝐿𝐿 − 𝑅𝑅) −  𝐺𝐺(𝐿𝐿) − 𝐺𝐺(𝑅𝑅) (2) 
The free energy decomposed in the following terms: 
𝐺𝐺 = 〈𝐸𝐸𝑀𝑀𝑀𝑀〉 + 〈𝐺𝐺𝑠𝑠𝑠𝑠𝑠𝑠〉 + 〈𝐺𝐺𝐵𝐵𝑠𝑠𝑛𝑛𝑠𝑠𝑠𝑠〉 − 𝑇𝑇〈𝑆𝑆𝑀𝑀𝑀𝑀〉 (3) 
The free energy change is then conveniently split: 
Δ𝐺𝐺𝐵𝐵𝐵𝐵𝐵𝐵𝐵𝐵 = Δ𝐺𝐺𝑛𝑛𝐵𝐵𝐵𝐵𝐵𝐵𝐵𝐵𝐵𝐵 + Δ𝑆𝑆𝑀𝑀𝑀𝑀 (4) 
In Equation (3) the EMM corresponds to the potential energy of the system, as de-
scribed by the force-field; Gsol is the polar solvation energy, estimated by the Poisson–
Boltzmann equation [31]; Gnopol is the non-polar solvation energy, estimated by the solvent-
accessible surface area, a method included in the MMPBSA. T is the absolute equilibrium 
temperature, while SMM is the molecular entropy of the system. The sum of the first three 
terms on the right-hand side of the Equation (3) is conveniently defined as the Poisson–
Boltzmann free energy of binding ΔGPBBind (see Equation (4)). To estimate the absolute 
value of the free energy of binding ΔGBind the molecular entropy change ΔSMM is required. 
Since in this study two similar molecules, VR17-04 and enisamium, were compared for 
their ability to bind cytosine (+1 position of the catalytic site of nsp12), or alternatively two 
bound states VR17-04-cytosine or VR17-04-adenine were inquired, the respective entropy 
changes ΔSMM are considered similar. In this condition the Poisson–Boltzmann free energy 
of binding ΔGPBBind could be used to rank the selected molecular recognitions and/or the 
poses of the docking experiment. 
3. Results 
3.1. Enisamium Inhibits SARS-CoV-2 Infection in Cell Culture 
Previous experiments showed that enisamium (Figure 1A) can efficiently inhibit in-
fluenza virus replication in normal human bronchial epithelial (NHBE) cultures and A549 
cells, and to a lesser extent in Caco-2 cells [13]. Previous experiments have also demon-
strated that enisamium is not cytotoxic to these cells [13]. To test if enisamium can inhibit 
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pandemic SARS-CoV-2 replication in cell culture, we first incubated Caco-2 cells, a stand-
ard cell line for SARS-CoV-2 infection in vitro, with enisamium iodide or enisamium chlo-
ride for 6 h and subsequently infected the treated cells with SARS-CoV-2. After 48 h, inhi-
bition of viral infection was assessed by antigen staining for viral nucleoprotein expres-
sion and RT-qPCR for viral genome replication. We observed a significant reduction in 
both viral nucleoprotein expression (Figure 1B), a reduction in the cytopathic effect of the 
SARS-CoV-2 infection on Caco-2 cells (Figure 1C), and a 2-log reduction in the number of 
viral genome copies in the infected cells as a function of the enisamium concentration 
(Figure 1D,E). The IC50 for enisamium chloride in Caco-2 cells was 1.2 mM (~300 µg/mL), 
which is comparable to the inhibitory effect of enisamium on influenza A virus replication 
in Caco-2 cells [13]. 
To test if enisamium can inhibit coronavirus replication in NHBE cells, NHBE cells 
were incubated with enisamium iodide for 6 h and subsequently infected with alpha-coro-
navirus HCoV NL63. Analysis of the N gene RNA levels in infected NHBE cells showed 
a strong effect on viral RNA synthesis (Figure 2A) with an IC50 of ~60 µg/mL, implying 
that enisamium can inhibit coronavirus replication in NHBE cells in vitro. 
 
Figure 2. Enisamium inhibits HCoV-NL63 infection of NHBE cells and SARS-CoV-2 nsp12/7/8 activity in vitro. (A) Quan-
tification of HCoV-NL63 N mRNA levels in NHBE cells infected with HCoV-NL63 after treatment with enisamium chlo-
ride. (B). Inhibition of SARS-CoV-2 nsp12/7/8 RNA polymerase complex activity by ensamium as measured with a mini-
genome assay. Quantification is from n = 3 independently prepared reactions using the same nsp12/7/8 protein prepara-
tion. Error bars represent standard deviation. 
3.2. Enisamium Inhibits SARS-CoV-2 nsp12/7/8 Activity 
Previous experiments showed that enisamium can inhibit the influenza A virus RNA 
polymerase in vitro [13]. To test if enisamium can inhibit SARS-CoV-2 RNA synthesis in 
vitro, we used a recently established mini-genome assay [14]. This assay depends on the 
replication and transcription of an N-subgenomic mRNA that encodes the nanoluciferase 
gene by the minimal viral RNA polymerase complex nsp12/7/8 [14]. The addition of 
enisamium to the medium significantly inhibited the mini-genome signal in a concentra-
tion-dependent manner (Figure 2B). 
3.3. Enisamium Adopts a Conformation in Solution That Would Be Compatible with Hydrogen 
Bond Formation 
We previously showed that enisamium is metabolized to VR17-04, and that VR17-04 
can block influenza A virus RNA polymerase activity. A recent report also showed that 
VR17-04 can inhibit the activity of purified nsp12/7/8 in vitro [15]. The difference between 
enisamium and VR17-04 is the addition of a hydroxyl group to the methyl-pyridinium 
ring in VR17-04 (Figure 1A). The hydroxyl group allows VR17-04 to adopt two confor-
mations that cannot be distinguished in enisamium. In particular, this hydroxyl group 
could be positioned parallel or opposite the carbonyl group that enisamium and VR17-04 
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share (Figure 3A), which we define as the eclipsed or trans conformations, respectively. In 
the eclipsed conformation, the hydroxyl and carbonyl groups of VR17-04 can form two 
hydrogen bonds using both a proton donor (H-O) and proton acceptor (O=C), potentially 
with a single interaction partner, while in the trans conformation, single hydrogen bonds 
could be made on both sides of VR17-04, potentially with two interaction partners. Quan-
tum chemical calculations suggest that the eclipsed conformation of VR17-04 has a lower 
energy in unbound state than the trans conformation (Table 1), and thus that the eclipsed 
conformation would likely be favored in solution. 
 
Figure 3. NMR spectrum of enisamium metabolite VR17-04. (A) Schematic of the trans and eclipsed 
conformations of VR17-04. Dihedral angles are indicated with φ. (B) 2D-NOESY and 1H proton 
spectra of VR17-04 acquired at 277 K in water. The NOE correlation between the HN and H5′ proton 
is highlighted with a dashed line. (C) 2D-NOESY and 1H proton spectra of VR17-04 acquired at 277 
K in DMSO. The NOE correlation between the HN and H5′ proton is highlighted as in panel B. 
To investigate the mechanism by which enisamium metabolite VR17-04 inhibits the 
SARS-CoV-2 nsp12/7/8 complex, we needed more information on the conformation of 
VR17-04 in solution and in a bound state of VR17-04 with the RNA polymerase complex. 
The conformations of VR17-04 and enisamium are characterized by four dihedral angles: 
φ0, φ1, φ2 and φ3 (Figure 3A). Dihedral φ3 allows us to differentiate between the trans and 
eclipsed conformations of VR17-04, since its angle is 141° in the trans conformation and −3° 
in the eclipsed conformation (Figure 3A). Moreover, dihedral φ3 defines that HN and H5′ 
are proximal in eclipsed conformation, and opposite in the trans conformation (Figure 3B 
and C inset). To experimentally determine which conformation VR17-04 adopts in solu-
tion (unbound state), we measured the 1H NOESY spectrum of VR17-04 in water, in which 
SARS-CoV-2 nsp12/7/8 is active, and DMSO, in which VR17-04 is initially dissolved (Fig-
ure 3B,C). In both solutions, we observed a NOEs correlation peak between the protons 
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HN and H5′, compatible with φ3 →  0° (Figure 3B,C). In addition, we observed a NOEs 
correlation between HN and CH2, and between HN and the ortho aromatic protons of the 
Ph group (H5, H3 in Figure 3C). The chemical shifts of the selected protons are reported 
in Table 2. Together these observations suggest that VR17-04 preferentially adopts an 
eclipsed conformation in an aqueous solution. 
Table 2. 1H chemical shift of the VR17-04 in water at T = 277 K acquired at 500 MHz. The labelled 
resonances are reported on the NOE spectra in Figure 4B. 
1H Resonance. HN H2′ H6′ H5′ Ph CH2 CH3 
δ ppm 10.45 8.29 8.08 8.13 7.42/7.36 4.66 4.28 
 
Figure 4. Molecular docking of VR17-04 binding into the nsp12/7/8 complex. (A) Schematic of putative hydrogen bond 
formation between cytosine and adenine bases with VR17-04. (B) Structure of the SARS-CoV-2 nsp12/7/8 complex bound 
to RNA and remdesivir monophosphate. Rendering based on PDB 7bv2. (C) Docking of VR17-04 binding to cytosine in 
nsp12 active site. (D) Docking of enisamium binding to cytosine in nsp12 active site. (E) Docking of VR17-04 binding to 
adenine in nsp12 active site. 
3.4. VR17-04 Forms Hydrogen Bonds with Cytosine and Adenosine in MD Simulations 
Enisamium metabolite VR17-04 inhibits the activity of the influenza A virus [13] and 
SARS-CoV-2 nsp12 RNA polymerases (Figure 2B), suggesting that it targets a conserved 
site. As noted above, in the eclipsed conformation, the OH group on the methyl-pyridinium 
ring and the central CO group could form two hydrogen bonds with an interaction part-
ner. This type of interaction is reminiscent of base-pairing between RNA or DNA strands, 
and we hypothesized that VR17-04 could form two hydrogen bonds with adenine and 
cytosine (Figure 4A). In this model, enisamium would only form one hydrogen bond with 
a cytosine or adenine in the template strand, resulting in a weaker interference with the 
RNA replication process. Interestingly, in this model VR17-04 would form no or only one 
hydrogen bond with guanine or uridine (Figure 4A), suggesting that no stable Watson–
Crick pair can be formed and that the inhibitory effect of VR17-04 would be dependent on 
the template sequence. 
To investigate the hypothesis that VR17-04 could form base-pair interactions with the 
template in the SARS-CoV-2 nsp12/7/8 active site, we docked enisamium or VR17-04 into 
the SARS-CoV-2 nsp12/7/8 complex bound to template RNA and remdesivir monosphos-
phate (PDB 7bv2, Figure 4B). Prior to docking, we removed the remdesivir monosphos-
phate from the complex, and used in silico mutagenesis to change the now unpaired uri-
dine in the template to cytosine or adenine. As shown in Figure 4C–E, we found that both 
enisamium and VR17-04 can be accommodated in the +1 position of the nucleotide bind-
ing pocket, in a position similar to remdesivir monosphosphate (Figure 4B). VR17-04 was 
specifically coordinated through hydrogen bond interactions with the unpaired cytosine 
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or adenine base in the template RNA. In addition, our modelling suggests that VR17-04 
can form a stacking interaction with the -1 base of the nascent strand. Nsp12 residues K545 
and K555 were observed to play a role in coordinating VR17-04 in the catalytic cavity. By 
contrast, enisamium docked in the same +1 nascent strand position, but only formed one 
hydrogen bond with the cytosine in the +1 template position. 
To estimate the binding stability of enisamium or VR17-04 in the nsp12 active cavity, 
we performed MD simulation of VR17-04 or enisamium docked in the nsp12/7/8 complex 
(Figure 5A,B; see Materials and Methods for specifics). Our MD simulations predict that 
VR17-04 binds more favorably to the unpaired cytosine in the +1 position of nsp12/7/8 
complex than enisamium, maintaining two hydrogen bonds (Watson–Crick base pair) at 
standard distances (Figure 5C,D) and a low coplanarity angle χ (Figure 5E). This is partic-
ularly evident from the ~2-fold difference in distance between enisamium and cytosine 
compared to VR17-04 and cytosine (Table 3, Figure 5C,D), and a higher estimated Pois-
son–Boltzmann free energy for the enisamium binding (43.6 kcal/mol) compared to VR17-
04 binding to either cytosine (-19.8 kcal/mol) or adenine (-14.8 kcal/mol) (Table 4). We 
observed similar hydrogen bond distances and dihedral angles in our MD simulations of 
VR17-04 binding of cytosine and adenine (compare Figure 5C,F, and see Figure 5G), sug-
gesting that both may be able to bind in the nsp12/7/8 complex active site. 
Table 3. Structural characterization of the interaction (Watson–Crick base pair) between VR17-04-cytosine (Cyt), 
enisamium-(Cyt), and VR17-04-adenine (Ade), described by average distances 〈d〉 between hydrogen bond donor and 
acceptor groups, and average values of the coplanarity angle 〈χ〉. The errors on the mean values are smaller than the last 
decimal digit. The selected distances and dihedrals are defined by the atoms in bold. The average interval is reported. 
Complex D 〈d〉 (Å) χ 〈χ〉(°) Avg Interval (ns) 
VR17-04-RdRp(C) CO---H2N-Cyt, OH---:N-Cyt 1.9, 2.4 CO-HN-N:-HO 13 30–50 
Enisamium-RdRp(C) CO---H2N-Cyt 3.3 CO-HN-N:-HC 20 30–50 
VR17-04-RdRp(A) CO---H2N-Ade, OH---:N-Ade 1.9, 2.9 CO-HN-N:-HO 11 20–40 
 
Figure 5. MD simulations of VR17-04 binding to nsp12/7/8. (A) MD simulation snapshot of VR17-04 binding to cytosine 
in nsp12 active site. Black dotted lines indicate hydrogen bonds. Template is shown in bright orange and nascent strand 
in dark red. Grey spheres represent magnesium ions. Positive charges on amino acids and base are dark blue and negative 
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charges light red. Nsp12 is colored light blue and shown in a cartoon presentation. (B) MD simulation snapshot of 
enisamium binding to cytosine in nsp12 active site. Colors as in Figure 5A. (C) MD simulation plot of hydrogen bond 
distances during VR17-04 binding to cytosine in nsp12 active site (left) and histogram of hydrogen bond distances (right). 
(D) MD simulation of hydrogen bond distance (C=O---HN-Cyt, blue color) during enisamium binding to cytosine in nsp12 
active site. Since no second hydrogen bond can form in the case of enisamium binding to nsp12/7/8, the distance C-H---
HN-Cyt is reported in magenta color for comparison. (E) MD simulation plot of the coplanarity angle of VR17-04 or 
enisamium binding to cytosine in nsp12 active site. (F) MD simulation of hydrogen bond distances during VR17-04 bind-
ing to adenine in nsp12 active site. (G) MD simulation of coplanarity angle of VR17-04 binding to cytosine or adenine in 
nsp12 active site. 
Table 4. Poisson Boltzmann free energy of binding 〈∆GPBBind〉 estimated as average value using the MMPBSA methods; the 
corresponding error on the mean is reported in brackets. The time interval for the average estimation is reported. 
Inhibitor Complex Average MD 
interval (ns) 
〈∆GPBBind〉 (kcal mol−1) 
VR17-04 VR17-04-RdRp(Cyt) [46, 50] −19.8(4) 
Enisamium Enisamium-RdRp(Cyt) [46, 50] 43.6(5) 
VR17-04 VR17-04-RdRp(Ade) [28, 32] −14.8(5) 
4. Discussion 
The rapid global spread of SARS-CoV-2 necessitates the development of effective 
therapeutic interventions, and the most promising short-term strategy is to repurpose ex-
isting drugs. In this study we showed that enisamium, which is approved for use against 
influenza in 11 countries, can inhibit SARS-CoV-2 infection and RNA synthesis in vitro 
(Figures 1 and 2). MD simulation analysis and in vitro activity assays suggest that VR17-
04 reversibly binds the exposed cytosine or adenine, preventing GTP and UTP incorpora-
tion into the nascent RNA chain (Figures 4 and 5). The inhibition of nsp12/7/8 by VR17-04 
is in line with previous in vitro activity assays with purified nsp12/7/8 [15]. 
It was previously reported that enisamium inhibits the influenza A virus RNA poly-
merase activity in vitro with a relatively high IC50 value of 46.3 mM [13]. This inhibition 
was improved 55-fold by the addition of a hydroxyl group in the compound VR17-04 [13]. 
A similar result was found for the SARS-CoV-2 nsp12/7/8 complex in a comparable in 
vitro assay [15]. Remdesivir triphosphate is the active metabolite of remdesivir, which has 
shown promise in both cell culture and clinical trials as a treatment for SARS-CoV-2 in-
fection [16]. We observed that the inhibitory effect of enisamium was more pronounced 
in NHBE cells than in Caco-2 cells, which is in line with previous influenza A virus exper-
iments [13,17] and suggests that enisamium is more readily metabolized into VR17-04 in 
primary bronchial epithelial cells compared to adenocarcinoma cells. 
Our docking and MD simulations suggest that VR17-04 can bind a template cytosine 
or adenine base in the active site of the SARS-CoV-2 RNA polymerase, forming a Watson–
Crick base pair interaction. This hypothesis is supported by our NOE experiments per-
formed in water, which indicate that VR17-04 can adopt an eclipsed conformation in solu-
tion (unbound state). We predict that the eclipsed conformation is compatible with a se-
quence-specific inhibition of the nsp12/7/8 RNA polymerase. Future activity and struc-
tural studies can be performed to further uncover the molecular mechanism by which 
VR17-04 and enisamium inhibit the SARS-CoV-2 RNA polymerase, or other RNA virus 
RNA polymerases. 
Overall, our results strongly suggest that enisamium metabolite VR17-04 inhibits 
RNA synthesis by the SARS-CoV-2 nsp12/7/8 complex. Moreover, unlike remdesivir, 
enisamium does not require intravenous administration, which would be advantageous 
for its use outside a hospital setting. Together with observations that enisamium can in-
hibit other RNA virus infections, and DNA virus infections [17,18], these results here sug-
gest that it can act as a broad-spectrum polymerase inhibitor in vitro. 
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